|  |
| --- |
| **Supplementary Table 1. Characteristics of Patients According to Antibiotic Therapy and Treatment Location** |
| **Daptomycin** |  | **Vancomycin** |
| n=73 (%) | **Home** | n=137 (%) |
|  | OPAT Diagnosis |  |
| 4 (5.5) |  Skin and Soft Tissue Infection | 8 (5.8) |
| 19 (26.0) |  Bone/Joint Infection | 28 (20.4) |
| 27 (37.0) |  Hardware-Associated Infection | 51 (37.2) |
| 9 (12.3) |  Diabetic Ulcer Infection | 26 (19.0) |
| 6 (8.2) |  Endocarditis | 10 (7.3) |
| 8 (11.0) |  Bacteremia/Endovascular Infection | 14 (10.2) |
| 19 (26.0) | Charlson Comorbidity Index >1 | 57 (41.6) |
|  | Medical Insurance |  |
| 44 (60.3) |  Private Insurer | 69 (50.4) |
| 17 (23.3) |  Medicare | 50 (36.5) |
| 0.7 (0.4-1.1) | Clinic Interactions Per Week of OPATa | 1.1 (0.7-1.8) |
| 54 (74.0) | Safety Labs Available Weekly | 112 (81.8) |
|  |  |  |
| n=32 (%) | **Rehab/Extended Care Facility** | n=175 (%) |
|  | OPAT Diagnosis |  |
| 1 (3.1) |  Skin and Soft Tissue Infection | 10 (5.7) |
| 13 (40.6) |  Bone/Joint Infection | 48 (27.4) |
| 5 (15.6) |  Hardware-Associated Infection | 67 (38.7) |
| 6 (18.8) |  Diabetic Ulcer Infection | 23 (13.1) |
| 5 (15.6) |  Endocarditis | 18 (10.3) |
| 2 (6.3) |  Bacteremia/Endovascular Infection | 9 (5.1) |
| 18 (56.3) | Charlson Comorbidity Index >1 | 91 (52.0) |
|  | Medical Insurance |  |
| 7 (21.9) |  Private Insurer | 62 (35.4) |
| 18 (56.3) |  Medicare | 92 (52.6) |
| 0.5 (0.3-1.0) | Clinic Interactions Per Week of OPAT | 0.7 (0.5-1.3) |
| 17 (53.1) | Safety Labs Available Weekly | 130 (74.3) |

*aData presented as median (interquartile range)*